Tirzepatide Side Effects vs Semaglutide
How tirzepatide and semaglutide compare on nausea, constipation, and other side effects — and how to choose based on your history.
Updated May 6, 2026 · 5 min read
The honest answer to "which has worse side effects" is: they're roughly tied. Total GI side-effect rates are very similar between tirzepatide and semaglutide. What differs is which symptoms are most prominent.
If you've never been on either, that distinction is academic. If you've been on one and struggled, it can predict whether the other will be easier — or just rough in a different way.
Side-by-side label rates
Numbers are approximate and pulled from the FDA labels for Zepbound (tirzepatide for weight management) and Wegovy (semaglutide for weight management). Trial populations and definitions differ slightly, so treat these as orienting figures, not exact comparisons.
| Side effect | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide 5–15 mg) |
|---|---|---|
| Nausea | ~44% | ~28–33% |
| Diarrhea | ~30% | ~19–23% |
| Vomiting | ~24% | ~10–13% |
| Constipation | ~24% | ~17–20% |
| Abdominal pain | ~20% | ~9–11% |
| Indigestion / dyspepsia | ~9% | ~9–10% |
| Injection site reactions | ~5–10% | ~5–10% |
| Fatigue | ~11% | ~5–7% |
A few patterns:
- Nausea is meaningfully lower on tirzepatide. This is the single most reliable difference. Trials, real-world data, and patient surveys all agree.
- Constipation rates look lower on the label for tirzepatide, but the persistence is different. On semaglutide, constipation tends to fade after the first 8–12 weeks. On tirzepatide, it often becomes the dominant ongoing complaint at maintenance dose.
- Vomiting is notably lower on tirzepatide — partly a consequence of the lower nausea, partly a separate signal.
Why the profile differs
The mechanism difference is the cleanest explanation. GIP activation (which tirzepatide adds) appears to attenuate some of the gastric-stasis and nausea effects that pure GLP-1 activation drives. See how tirzepatide works for the receptor story.
But GIP activation slows things differently in the lower GI tract — leaving constipation as the more durable complaint. The drug isn't gentler overall; it's redistributing the trouble lower.
Real-world reports vs trial data
Trial populations are highly motivated, closely monitored, and titrated slowly. Real-world dosing tends to ramp faster (especially in compounded settings), and real-world tolerability looks rougher than the labels suggest for both drugs. With that caveat, online communities and clinician surveys consistently report:
- Tirzepatide users complain about constipation, mild nausea after each dose, and fatigue in early weeks.
- Semaglutide users complain about persistent nausea, vomiting in early weeks, and "sulfur burps" (more on those below).
- Both produce significant fatigue in the first 4–8 weeks, fading as the body adapts.
- Both produce reflux and heartburn in roughly comparable rates — see heartburn and reflux for management.
The "sulfur burp" and gastric retention story
Sulfur burps — the rotten-egg-smelling belches — are anecdotally more common on semaglutide than tirzepatide. The cause is incompletely understood but appears tied to slowed gastric emptying and changes in protein digestion. Some users find them uniquely awful and switch drugs primarily to escape them.
Tirzepatide's gastric retention is real but generally produces fullness, mild reflux, and occasional nausea rather than the sulfur-burp pattern.
Less common but more serious effects
Both drugs share the same boxed warning and serious-adverse-event categories:
- Pancreatitis. Rare. Severe upper-abdominal pain radiating to the back, especially with vomiting, is an emergency. See pancreatitis.
- Gallbladder issues. Rapid weight loss raises gallstone risk independent of the drug. See gallbladder.
- Thyroid C-cell tumors. Black-box warning based on rodent data. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2.
- Diabetic retinopathy worsening. Documented for semaglutide in T2D trials; the tirzepatide signal is less established but plausible.
- Hypoglycemia when combined with insulin or sulfonylureas. Either drug.
These rates don't differ meaningfully between the two drugs. Choose on the GI profile, not the rare-event profile.
How to choose based on your history
A practical decision framework:
| Your history | Lean toward |
|---|---|
| Severe nausea on past GLP-1s | Tirzepatide — lower nausea rates, especially during titration. |
| Chronic constipation, IBS-C, low-fiber diet | Semaglutide — constipation is more manageable on average. |
| Sulfur burps were your main complaint on sema | Tirzepatide — much rarer. |
| Bad reflux unrelated to GLP-1s | Either — both can worsen reflux equally. |
| Vomiting that broke your adherence on sema | Tirzepatide — vomiting is meaningfully less common. |
| First time on a GLP-1, no preferences | Tolerability is comparable; choose on cost, coverage, or weight-loss goals. |
Coping strategies that work for both
Most GI side-effect tactics translate across the class. Quick wins:
- Smaller, more frequent meals. Both drugs slow gastric emptying. Big meals overwhelm the system.
- Hydration first thing in the morning. Slowed emptying makes you forget to drink. Set a reminder.
- Fiber up — slowly. 25–35 g/day. Ramp gradually so you don't trade constipation for bloating.
- Magnesium citrate (200–400 mg at night) for tirzepatide-driven constipation. Cheap and reliable. See the constipation playbook.
- Wait through titration weeks 1–2. The worst side effects fade quickly at each step. Many people abandon early when they were 7 days from feeling better.
For deeper coping playbooks, see nausea and constipation on the side-effects pillar.
Switching as a side-effect strategy
Switching from one drug to the other purely to escape a side effect is reasonable when:
- You've genuinely titrated patiently and the symptom hasn't resolved
- The side effect is meaningfully degrading your quality of life
- You have insurance coverage or budget for both options
Many people who tried semaglutide and stopped because of nausea do well on tirzepatide. The reverse is less common but happens with severe constipation. The switch itself is uncomplicated — see tirzepatide vs semaglutide for the protocol.